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We thank Dr Shor for his intriguing comments regarding the role of Chlamydia pneumoniae in atherosclerosis. We agree that strong evidence links products of Chlamydia pneumoniae with atherogenesis and lipid metabolism by macrophages. Indeed, our own data support a novel role for Chlamydia pneumoniae heat shock protein as a pro-inflammatory mediator and have defined the involvement of CD14 in the molecular signaling of this pathway. 1,2 Kalayoglu, in Byrne's laboratory, found that the chlamydial heat shock protein-60 promotes cellular oxidation of low-density lipoprotein, 3 and that chlamydial endotoxin induces macrophage foam cell formation. 4 This work, as well as related findings from other groups, provides a firm pathophysiological foundation for potential involvement of Chlamydia in atherosclerosis and local lipoprotein metabolism within atheroma.
Despite this fascinating basic science, translation to the clinic remains problematic. The recent preliminary reports of the Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders (WIZARD) study results showed no effect of 12 weeks of azithromycin treatment in survivors of myocardial infarction. 5 These negative clinical trials in no way refute the hypothesis that Chlamydia can potentiate atherogenesis, as Gieffers et al found that azithromycin cannot eradicate intracellular Chlamydia pneumoniae in human monocyte/macrophages. 6 The ongoing Azithromycin and Coronary Events Study (ACES) is evaluating longer term treatment with azithromycin (12 months) in survivors of myocardial infarction. The PRavastatin Or atorVastatin Evaluation and Infection Therapy (PROVE-IT) study will assess the effects of the fluoroquinolone antibiotic gatafloxicin in patients with acute coronary syndromes.
We currently view the evidence for a role of Chlamydia in atherosclerosis as follows: 1) Seroepidemiological evidence supporting a role for Chlamydia in atherosclerosis and coronary events remains unconvincing.
2) A concordant data set suggests that human atherosclerotic plaques may contain Chlamydia pneumoniae, in agreement with Dr Shor's observations, but the prevalence of such infection may exhibit regional, racial, and age-related differences. In conclusion, we share Dr Shor's fascination with the possible role of Chlamydia pneumoniae in atherogenesis. We believe that chlamydial infection, if present, might potentiate atherosclerosis, acting in concert with risk factors such as disorders of lipid metabolism, rather than as a sole etiologic agent in the vast majority of cases.
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